Knee Joint Swelling at Presentation: A Case of Pediatric Crohn Disease With a TNFAIP3 Mutation
- 1 December 2020
- journal article
- research article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 146 (6)
- https://doi.org/10.1542/peds.2019-3416
Abstract
Crohn disease (CD) is a chronic inflammatory disease, and its incidence in children is rising. Despite extensive reports and investigations, the pathogenesis of CD has not been clearly elucidated, particularly in regard to triggering factors. A genetic predisposition is considered important when investigating the mechanism leading to CD, and the discovery of new CD-associated genes has increased our understanding of its immunopathogenesis and improved the efficacy of its treatment of CD. Early detection and treatment (eg, as children) with gene-based precision therapy can effectively prevent complications related to CD. In this case, a Chinese Han boy with CD associated with a mutation of tumor necrosis factor alpha-induced protein 3 was treated with recombinant human tumor necrosis factor-a receptor II:IgG Fc fusion protein. We suspected the boy had CD because of chronic abdominal pain, aphthous stomatitis, moderate anemia, a high erythrocyte sedimentation rate (36-79 mm/h), multiple intestinal ulcers, knee joint swelling, and a tumor necrosis factor alpha-induced protein 3 mutation. After total enteral nutrition and hormone therapy for 5 months, his abdominal pain and joint symptoms did not improve, so we started gene-based precision therapy with recombinant human tumor necrosis factor-a receptor II: IgG Fc fusion protein, which may play an important role in restricting TNF-alpha-induced NF-kappa B signaling. After 3 weeks, inflammation indicators were within the normal range, and multiple ulcers and joint symptoms were relieved. The present case demonstrates a safe therapeutic schedule that leads to rapid improvements in the clinical and biochemical status of patients with CD. Pediatric patients with CD induced by a TNFAIP3 mutation (had knee joint swelling at presentation).This publication has 35 references indexed in Scilit:
- Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2013
- Patients With Ulcerative Colitis Miss More Days of Work Than the General Population, Even Following ColectomyGastroenterology, 2013
- Crohn's diseaseThe Lancet, 2012
- Host–microbe interactions have shaped the genetic architecture of inflammatory bowel diseaseNature, 2012
- Genetics and pathogenesis of inflammatory bowel diseaseNature, 2011
- Comparing the Tuberculin Skin Test and T-SPOT.TB Blood Test in ChildrenPublished by American Academy of Pediatrics (AAP) ,2011
- Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-γThe Journal of Experimental Medicine, 2005
- Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitisAnnals Of The Rheumatic Diseases, 2003
- Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.Gut, 1993
- Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.Gut, 1991